WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m

Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market

Exicure, Inc. (NASDAQ:XCUR) (the "Company") today announced that it received a notification

Exicure (NASDAQ:XCUR) reported quarterly losses of $(0.29) per share. This is a 159.18 percent decre

Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hema

Exicure (NASDAQ:XCUR) reported quarterly losses of $(0.22) per share. This is a 93.51 percent increa

On February 11, 2026, the board of directors (the "Board") of Exicure, Inc. (the "Compan

Exicure shares trade higher after Phase 2 data show nearly 90% of patients reached key cell collecti

XCUR: 176% | Exicure shares are trading higher after the company announced results from its complete

Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hema

Burixafor Phase 2 Trial in Multiple Myeloma Nears Key Clinical ReadoutExicure's ongoing Phase 2

Exicure (NASDAQ:XCUR) reported quarterly losses of $(0.41) per share. This is a 17.14 percent decrea

Topline results expected H2 2025Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company

U.S. stock futures up, focus on PRGS, XCUR, QMCO earnings. VERO jumps 43.6% after stake increase, I

Exicure (NASDAQ:XCUR) reported quarterly earnings of $0.49 per share. This is a 202.08 percent incre

The Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeut